• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Quick Take: Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome

byAliya Ramjaun
October 6, 2019
in Cardiology, Chronic Disease, Emergency
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The risk of major cardiovascular events may be further reduced with the addition of fenofibrate therapy to statin treatment in adults with metabolic syndrome.

Evidence Rating Level: 2 (Good)

Metabolic syndrome is associated with an increased risk of atherosclerotic cardiovascular disease; this risk is partly attributable to accompanying atherogenic dyslipidemia. While statin therapy significantly reduces low density lipoprotein (LDL) cholesterol concentrations and therefore reduces the risk of cardiovascular disease, many patients continue to have significant cardiovascular risk. Fenofibrate has been suggested as a treatment option or adjunct in the management of dyslipidemia. Although previous large randomized clinical trials failed to demonstrate a reduction in major cardiovascular populations with diabetes, risk reduction was observed in subgroups with atherogenic dyslipidemia. In this population-based cohort study, adults in Korea age 40 years or older with metabolic syndrome receiving statin treatment (2007-2014) were followed up to evaluate the effects of fenofibrate treatment on major cardiovascular events (MACE) in adults with metabolic syndrome on statin therapy. Of the 29,771 individuals forming the initial cohort, 2156 participants were receiving combined treatment, and were thus weighted based on propensity scoring in a 1:5 ratio with 8549 patients using statin only treatment. Researchers found that the incidence per 1000 person-years of composite cardiovascular events was 17.7 (95% CI 14.4 to 21.8) in the combined treatment group, as compared to 22.0 (95% CI 20.1 to 24.1) in the statin-only group. This translated to a significantly reduced risk of cardiovascular events (HR 0.74, 95% CI 0.58 to 0.93). The risk of incident coronary heart disease, stroke, and cardiovascular death were also lower in the combined treatment group, however, these findings were not significant. This study therefore shows that the risk of major cardiovascular events may be further reduced with the addition of fenofibrate therapy to statin treatment in adults with metabolic syndrome.

Click to read the study in BMJ

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

Tags: cardiovascular riskfenofibratehyperlipidemiametabolic syndromeobesity
Previous Post

Vitamin C may not provide benefit in sepsis with acute respiratory failure

Next Post

Quick Take: Factors associated with successful discontinuation of immune suppression after allogenic hematopoietic cell transplantation

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults
StudyGraphics

#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults

June 16, 2025
#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes
StudyGraphics

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

May 20, 2025
Food environment associated with gestational diabetes
Pharma

Eli Lilly Takes Legal Action Against Telehealth Startups

May 15, 2025
Next Post
Quick Take: Factors associated with successful discontinuation of immune suppression after allogenic hematopoietic cell transplantation

Quick Take: Factors associated with successful discontinuation of immune suppression after allogenic hematopoietic cell transplantation

#VisualAbstract: Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia

#VisualAbstract: Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia

Downward trend in mortality rate for antineutrophil cytoplasmic autoantibody-associated vasculitis

Downward trend in mortality rate for antineutrophil cytoplasmic autoantibody-associated vasculitis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.